trial · primary record
Durvalumab
Cancer
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 214 |
| Primary completion | 2027-12-31 |
| Primary endpoint | Number of participants with serious adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 |
| Registry ID | NCT05303532 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:18.041Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05303532
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.